“Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor”. Medicinal Research Reviews36 (4): 749–86. (July 2016). doi:10.1002/med.21392. PMID27140825.
“Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy”. Pharmaceutical Research29 (9): 2499–511. (September 2012). doi:10.1007/s11095-012-0780-y. PMID22678771.
“Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody”. The Journal of Biological Chemistry278 (10): 8468–75. (March 2003). doi:10.1074/jbc.M211202200. PMID12493754.
“Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression”. Oncogene23 (4): 865–72. (January 2004). doi:10.1038/sj.onc.1207223. PMID14647413.
“M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex”. The Journal of Biological Chemistry278 (38): 35979–87. (September 2003). doi:10.1074/jbc.M210659200. PMID12815053.
“Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner”. Human Molecular Genetics15 (2): 287–97. (January 2006). doi:10.1093/hmg/ddi444. PMID16339216.
“Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor”. Medicinal Research Reviews36 (4): 749–86. (July 2016). doi:10.1002/med.21392. PMID27140825.
“Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy”. Pharmaceutical Research29 (9): 2499–511. (September 2012). doi:10.1007/s11095-012-0780-y. PMID22678771.
“Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody”. The Journal of Biological Chemistry278 (10): 8468–75. (March 2003). doi:10.1074/jbc.M211202200. PMID12493754.
“Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression”. Oncogene23 (4): 865–72. (January 2004). doi:10.1038/sj.onc.1207223. PMID14647413.
“M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex”. The Journal of Biological Chemistry278 (38): 35979–87. (September 2003). doi:10.1074/jbc.M210659200. PMID12815053.
“Polo-like kinase interacts with proteasomes and regulates their activity”. Cell Growth & Differentiation12 (1): 29–37. (January 2001). PMID11205743.
“Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner”. Human Molecular Genetics15 (2): 287–97. (January 2006). doi:10.1093/hmg/ddi444. PMID16339216.